Your SlideShare is downloading. ×
Generics+in+Cardiovascular+Diseases+Market+to+2018+-+Loss+of+Lipitor+Market+Exclusivities+and+Impending+Patent+Expirations+of+Plavix+to+Drive+Generic+Substitution
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Generics+in+Cardiovascular+Diseases+Market+to+2018+-+Loss+of+Lipitor+Market+Exclusivities+and+Impending+Patent+Expirations+of+Plavix+to+Drive+Generic+Substitution

1,349
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,349
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Generics in Cardiovascular Diseases Market to 2018 - Loss ofLipitor Market Exclusivities and Impending Patent Expirationsof Plavix to Drive Generic SubstitutionReport Details:Published:May 2012No. of Pages: 129Price: Single User License – US$3500Corporate User License – US$10500Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities andImpending Patent Expirations of Plavix to Drive Generic SubstitutionSummaryGBI Research, the leading business intelligence provider, has released its latest research“Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities andImpending Patent Expirations of Plavix to Drive Generic Substitution”. The report provides in-depthanalysis of drivers and barriers that impact the global cardiovascular disorders market. The reportanalyzes the generics market for cardiovascular disorders in the US, the top five countries inEurope (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns areforecast until 2018 for the key geographies as well as the leading therapeutic segments.Furthermore, the report provides competitive benchmarking for the leading companies andanalyzes the mergers, acquisitions and licensing agreements that shape the global markets.This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GBI Research’s team of industry experts.The global generics market cardiovascular drugs is expected to grow rapidly due to the growingdyslipdemia, thrombosis and hypertension populations in the developed countries, as well aspatent expiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan(valsartan). The patent expiries of these blockbuster drugs will trigger generic competition in thecardiovascular therapeutics market, making it more competitive.In 2010, the generics market for cardiovascular drugs was estimated at $20.5 billion, indicating ayear on year decline of 0.9% from 2004-2010. Patent expiries of the leadingantiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipid
  • 2. lowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected to cause themarket to increase significantly from 2010 to 2018.Scope- Annualized market data for the generics in cardiovascular disorders market from 2004 to 2010,forecast forward to 2018.- Analysis of the leading therapeutic segments, including pulmonary arterial hypertension,thrombosis, dyslipidemia, hypertension, coronary artery disease, and Angina Pectoris.- Analysis of the generics in cardiovascular disorders market in the leading geographies of theworld, which include the US, the UK, Germany, France, Italy, Spain and Japan.- Market characterization of the generics in cardiovascular disorders market, including market size,annual cost of treatment and treatment usage pattern.- Key drivers and barriers that have a significant impact on the generics market.- Coverage of pipeline molecules in various phases of drug development.- Competitive benchmarking of leading generic companies. The key companies studied in thisreport are- Key M&A activities, licensing agreements that have taken place from 2004 to 2011 in the globalcardiovascular disorders market.Reasons to buy- Build effective strategies to launch their pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might fill theirportfolio gaps.- Develop key strategic initiatives by studying the key strategies of top competitors.- Develop market-entry and market expansion strategies by identifying the geographic marketspoised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-classmolecules which are safer and more efficacious.Get your copy of this report @http://www.reportsnreports.com/reports/144406-generics-in-cardiovascular-diseases-market-to-2018-loss-of-lipitor-market-exclusivities-and-impending-patent-expirations-of-plavix-to-drive-generic-substitution.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Generics in Cardiovascular Diseases Market to 2018 – Introduction 123 Generics in Cardiovascular Diseases Market to 2018 - Global Market Overview 133.1 Introduction 13
  • 3. 3.1.1 Antidyslipidemics 133.1.2 Anti-Hypertensives 153.1.3 Rise in Generics in CVD Market 153.2 Revenue 163.3 Annual Cost of Therapy 183.4 Treatment Usage Patterns 193.4.1 Disease population 203.4.2 Treatment Seeking Population 203.4.3 Diagnosed Population 203.4.4 Prescription Population 204 Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape 214.1 The US 214.1.1 Revenue 214.1.2 Annual Cost of Therapy 224.1.3 Treatment Usage Patterns 244.2 Top Five Countries of Europe 264.2.1 Revenue 264.2.2 Annual Cost of Therapy 274.2.3 Treatment Usage Patterns 284.3 Japan 304.3.1 Revenue 304.3.2 Annual Cost of Therapy 314.3.3 Treatment Usage Patterns 325 Generics in Cardiovascular Diseases Market to 2018- Therapeutic Landscape 345.1 Thrombosis 345.1.1 Introduction 345.1.2 Revenue 355.1.3 Annual Cost of Therapy 365.1.4 Treatment Flow Algorithm 375.1.5 Treatment Usage Pattern 385.1.6 Drivers and Restraints 405.1.7 Drivers 405.1.8 Restraints 405.2 Pulmonary Arterial Hypertension 415.2.1 Introduction 415.2.2 Revenue 435.2.3 Annual Cost of Therapy 445.2.4 Treatment Usage Patterns 465.2.5 Treatment Flow Algorithm 485.2.6 Drivers and Restraints 485.2.7 Drivers 49
  • 4. 5.2.8 Restraints 495.3 Hypertension 505.3.1 Introduction 505.3.2 Revenue 515.3.3 Annual Cost of Therapy 525.3.4 Treatment Flow Algorithm for Hypertension 535.3.5 Treatment Usage Patterns 545.3.6 Drivers and Restraints 565.3.7 Drivers 565.3.8 Restraints 565.4 Dyslipidemia Market 575.4.1 Introduction 575.4.2 Revenue 575.4.3 Annual Cost of Therapy 595.4.4 Treatment Flow Algorithm 605.4.5 Treatment Usage Patterns 615.4.6 Drivers and Restraints 625.4.7 Drivers 635.4.8 Restraints 635.5 Coronary Artery Disease 645.5.1 Introduction 645.5.2 Revenue 645.5.3 Annual Cost of Therapy 665.5.4 Treatment Usage Patterns 675.5.5 Drivers and Restraints 695.5.6 Drivers 695.5.7 Restraints Market 705.6 Angina Pectoris Market 705.6.1 Introduction 705.6.2 Revenue 715.6.3 Cost of Therapy 725.6.4 Treatment Flow Algorithm 735.6.5 Treatment Usage Patterns 745.6.6 Drivers and Restraints 755.6.7 Drivers for the Angina Pectoris Market 765.6.8 Restraints for the Angina Pectoris Market 766 Generics in Cardiovascular Diseases Market to 2018 - Product Pipeline Analysis 776.1 Introduction 776.1.1 Research and Development Pipeline – Pulmonary Arterial Hypertension 786.1.2 Research and Development Pipeline – Dyslipidemia 816.1.3 Research and Development Pipeline – Coronary Artery Disease 87
  • 5. 6.1.4 Research and Development Pipeline – Angina Pectoris 896.1.5 Research and Development Pipeline – Thrombosis 896.1.6 Research and Development Pipeline – Hypertension 927 Generics in Cardiovascular Diseases Market to 2018 - Most Promising Pipeline Molecules 997.1 Eliquis 997.1.1 Introduction 997.1.2 Mechanism of Action 997.2 RG1658 (Dalcetrapib, JTT-705, RO4607381) 997.2.1 Introduction 997.2.2 Mechanism of Action 997.2.3 Clinical Trial Management 1 997.3 MK-0524A (Cordaptive, niacin + laropiprant) 1007.3.1 Introduction 1007.3.2 Mechanism of Action 1007.3.3 Clinical Trial Management 2 1007.4 AMR101 (LAX-101, Miraxion) 1017.4.1 Introduction 1017.4.2 Mechanism of Action 1017.4.3 Clinical Trial Management 3 1018 Generics in Cardiovascular Diseases Market to 2018 – Competitive Landscape 1028.1 Teva Pharma 1028.2 Sandoz 1028.3 Actavis 1028.4 Apotex 1028.5 Watson Pharmaceuticals 1038.5.1 Watson Launches First Generic Lipitor (atorvastatin) 1038.6 Mylan 1039 Generics in Cardiovascular Diseases Market to 2018 – Strategic Consolidations 1049.1 Merger and Acquisition Deals (2004-2011) 1049.1.1 Deals by Year 1069.1.2 M&A Deals by Region 1079.1.3 M&A Deals by Value 1089.1.4 Deal Summary of Top 10 M&A Deals by Value 1099.2 Licensing Deals 1119.2.1 Deals by Indication 1139.2.2 Deals by Geography 1149.2.3 Deals by Year 1159.2.4 Deal Summary of Top Five Licensing Deals by Value 1169.3 Co-development Deals 1179.3.1 Deals by Indication 1179.3.2 Deals by Geography 118
  • 6. 9.3.3 Deals by Year 1199.3.4 Deal Summary of Top Five Co-development Deals by Value 12010 Generics in Cardiovascular Diseases Market to 2018 - Appendix 12210.1 Market Definitions 12210.2 Abbreviations 12210.3 Sources 12310.4 Research Methodology 12410.4.1 Coverage 12410.4.2 Secondary Research 12510.4.3 Primary Research 12510.4.4 The report consists of the following four major sections 12510.4.5 Therapeutic Landscape 12610.4.6 Forecasting Model for Therapeutic Areas 12810.4.7 Geographical Landscape 12910.4.8 Pipeline Analysis 12910.4.9 Competitive Landscape 12910.4.10 Expert Panel Validation 12910.5 Contact Us 12910.6 Disclaimer 1291.1 List of TablesTable 1: Generics in Cardiovascular Diseases Market, Patent Expiries of Leading CardiovascularDrugs, 2011 14Table 2: Generics in Cardiovascular Diseases Market, Global, Revenue ($bn), 2004–2010 17Table 3: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn),2010–2018 17Table 4: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($),2004–2010 18Table 5: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($),2010–2018 18Table 6: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million),2004–2010 19Table 7: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million),2010–2018 20Table 8: Generics in Cardiovascular Diseases Market, The US, Revenue ($bn), 2004–2010 21Table 9: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn),2010–2018 22Table 10: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($),2004–2010 22Table 11: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($),2010–2018 23
  • 7. Table 12: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns(million), 2004–2010 24Table 13: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns(million), 2010–2018 24Table 14: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue($bn), 2004–2010 26Table 15: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, RevenueForecasts ($bn), 2010–2018 26Table 16: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, AnnualCost of Therapy($), 2004–2010 27Table 17: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, AnnualCost of Therapy ($), 2010–2018 27Table 18: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, TreatmentUsage Patterns (million), 2004–2010 28Table 19: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, TreatmentUsage Patterns (million), 2010–2018 28Table 20: Generics in Cardiovascular Diseases Market, Japan, Revenue ($bn), 2004–2010 30Table 21: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($bn),2010–2018 30Table 22: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($),2004–2010 31Table 23: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($),2010–2018 31Table 24: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns(million), 2004–2010 32Table 25: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns(million), 2010–2018 32Table 26: Generics in Thrombosis Market, Global, Revenue ($m), 2004–2010 35Table 27: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2010–2018 35Table 28: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2010 37Table 29: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2010–2018 37Table 30: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–201038Table 31: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2010–201838Table 32: Generics in Pulmonary Arterial Hypertension Market, Global Revenue ($m), 2004–201043Table 33: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m),2010–2018 44Table 34: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy($), 2004–2010 45
  • 8. Table 35: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy($), 2010–2018 45Table 36: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns,(‘000), 2004–2010 46Table 37: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns,(‘000), 2010–2018 46Table 38: Generics in Hypertension Market, Global, Revenue ($bn), 2004–2010 51Table 39: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2010–2018 51Table 40: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2010 52Table 41: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2010–2018 53Table 42: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2004–201054Table 43: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2010–201854Table 44: Generics in Dyslipidemia Market, Global, Revenue ($bn), 2004–2010 57Table 45: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2010–2018 58Table 46: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2010 59Table 47: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2010–2018 59Table 48: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2004–201061Table 49: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2010–201861Table 50: Generics in Coronary Artery Disease Market, Global, Revenue ($m), 2004–2010 65Table 51: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m),2010–2018 65Table 52: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($),2004–2010 66Table 53: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($),2010–2018 66Table 54: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million),2004–2010 67Table 55: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million),2010–2018 67Table 56: Generics in Angina Pectoris Market, Global, Revenue ($m), 2004–2010 71Table 57: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($m), 2010–2018 72Table 58: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2010 72Table 59: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2010–2018 72Table 60: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million),2004–2010 74Table 61: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million),2010–2018 74
  • 9. Table 62: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in PAH, 2011 78Table 63: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Regulatory andPhase III Research and Development Pipeline, 2011 81Table 64: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase II Researchand Development Pipeline, 2011 82Table 65: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase I Researchand Development Pipeline, 2011 84Table 66: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Pre-Clinical andDiscovery Research and Development Pipeline, 2011 85Table 67: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in CAD, 2011 88Table 68: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in Angina Pectoris, 2011 89Table 69: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in Thrombosis (%), 2011 90Table 70: Generics in Cardiovascular Diseases Market, Global, Hypertension Regulatory Filingand Phase III Research and Development Pipeline, 2011 92Table 71: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase II Researchand Development Pipeline, 2011 94Table 72: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase I Researchand Development Pipeline, 2011 95Table 73: Generics in Cardiovascular Diseases Market, Global, Hypertension Pre-clinical andDiscovery Research and Development Pipeline, 2011 96Table 74: Generics in Cardiovascular Diseases Market, Global, M&A Deals, 2010-2011 104Table 75: Generics in Cardiovascular Diseases Market, Global, Licensing Deals, 2010–2011 1111.2 List of FiguresFigure 1: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn),2004–2018 16Figure 2: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($),2004–2018 18Figure 3: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns(million), 2004–2018 19Figure 4: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn),2004–2018 21Figure 5: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($),2004–2018 22Figure 6: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns(million), 2004–2018 24Figure 7: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue
  • 10. Forecasts ($bn), 2004–2018 26Figure 8: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Costof Therapy($), 2004–2018 27Figure 9: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, TreatmentUsage Patterns (million), 2004–2018 28Figure 10: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($m),2004–2018 30Figure 11: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($),2004–2018 31Figure 12: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns(million), 2004–2018 32Figure 13: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2004–2018 35Figure 14: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2018 36Figure 15: Generics in Cardiovascular Diseases Market, Global, Thrombosis, Treatment FlowAlgorithm 37Figure 16: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–201838Figure 17: Generics in Thrombosis Market, Global, Drivers and Restraints, 2011 40Figure 18: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m),2004–2018 43Figure 19: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy($), 2004–2018 44Figure 20: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment UsagePatterns, (‘000), 2004–2018 46Figure 21: Generics in Cardiovascular Diseases Market, Global, Pulmonary Arterial Hypertension,Treatment Flow Algorithm, 2010 48Figure 22: Generics in Pulmonary Arterial Hypertension, Global, Drivers and Restraints, 2011 48Figure 23: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2004–2018 51Figure 24: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2018 52Figure 25: Generics in Cardiovascular Diseases Market, Global, Hypertension, Treatment FlowAlgorithm, 2011 53Figure 26: Generics in Hypertension Market, Global, Treatment Usage Pattern (million),2004–2018 54Figure 27: Generics in Hypertension Market, Global, Drivers and Restraints, 2010 56Figure 28: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2004–2018 57Figure 29: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2018 59Figure 30: Generics in Cardiovascular Diseases Market, Dyslipidemia, Treatment Flow Algorithm60Figure 31: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million),2004–2018 61Figure 32: Generics in Dyslipidemia Market, Global, Drivers and Restraints, 2010 62
  • 11. Figure 33: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m),2004–2018 64Figure 34: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($),2004–2018 66Figure 35: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern(million), 2004–2018 67Figure 36: Generics in Coronary Artery Disease Market, Global, Drivers and Restraints, 2011 69Figure 37: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($bn), 2004–2018 71Figure 38: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2018 72Figure 39: Generics in Cardiovascular Diseases Market, Global, Angina Pectoris, Treatment FlowAlgorithm 73Figure 40: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million),2004–2018 74Figure 41: Generics in Angina Pectoris Market, Global, Drivers and Restraints, 2011 75Figure 42: Generics in Cardiovascular Diseases Market, Global Product Pipeline by Indication (%),2011 77Figure 43: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in PAH (%), 2011 78Figure 44: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia Research andDevelopment Pipeline by Phase (%), 2011 81Figure 45: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in CAD (%), 2011 87Figure 46: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in Thrombosis (%), 2011 89Figure 47: Generics in Cardiovascular Diseases Market, Global, Research and DevelopmentPipeline by Phase in Hypertension (%), 2011 92Figure 48: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Year, 2004–2011106Figure 49: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Geography,2004–2011 107Figure 50: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Value ($m),2004–2010 108Figure 51: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Indication (%),2004–2011 113Figure 52: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Geography(%), 2004–2011 114Figure 53: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Year,2004–2011 115Figure 54: Generics in Cardiovascular Diseases Market, Global, Co-development Deals byIndication (%), 2004-2011 117Figure 55: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by
  • 12. Geography (%), 2004–2010 118Figure 56: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Year,2004-2011 119Figure 57: GBI Research Market Forecasting Model 128Contact: sales@reportsandreports.com for more information.